The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.17
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.03 (17.647%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Hunter Eleco's Permanent CEO; 600 Group CFO Leaves

Wed, 10th Feb 2021 15:25

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

Eleco PLC - construction software firm - Says Jonathan Hunter, who took on the role of interim chief executive back in September, has been appointed CEO on a permanent basis. Hunter was appointed to the board in June 2016, having held a number of senior management positions within Eleco since joining in 2010. He was appointed COO in 2017 prior to his appointment as interim CEO.

----------

600 Group PLC - West Yorkshire, England-based manufacturer and distributor of machine tools, precision engineered components and industrial laser systems - Says Chief Financial Officer Mitch Krasny steps down as a director with immediate effect by mutual agreement. A formal process to identify a successor has been initiated.

----------

GCP Infrastructure Investments Ltd - focuses primarily on investments in UK infrastructure debt - Says that, following conclusion of Wednesday's annual general meeting, Non-Executive Director David Pirouet has retired. Company appoints Steven Wilderspin, effective Wednesday. Wilderspin is currently a non-executive director at Blackstone Loan Financing Ltd and HarbourVest Global Private Equity Ltd.

----------

Mineral & Financial Investments Ltd - Cayman Islands-based investment company specialising in junior mining companies - Adds Mark Brown, president of Pacific Opportunity Capital Ltd, to the board as chair. Jacques Vaillancourt will assume the role of president, chief executive & director of the company.

----------

W Resources PLC - tungsten, tin and gold mining company - Says Non-Executive Director Oscar Marin Garcia will step down from the board on Friday to focus on increased commitments in his business. The search for a new non-executive is underway. Garcia says: "Whilst my current commitments mean I am unable to remain on the board of directors, I remain a strong advocate of W Resources and its operations in Spain and I intend to retain my beneficial shareholding in the company."

----------

Nuformix PLC - pharmaceutical development firm based in London - Says Chris Blackwell has resigned as non-executive chair and director of the company with immediate effect "due to personal reasons that require his immediate attention". A process to appoint a new chair will start immediately.

----------

Smith & Nephew PLC - medical devices manufacturer - Appoints John Ma as a non-executive director. Since 2019, he has served as chief executive & chair of Ronovo Surgical, a start-up soft tissue surgical robotics business he founded. "We are delighted to have secured a Board colleague with John's track record growing medical device businesses across China and the wider region," says Smith & Nephew Chair Roberto Quarta.

----------

Ground Rents Income Fund PLC - real estate investment trust - Appoints Barry Gilbertson as a non-executive director, effective Wednesday. He was recently appointed as executive chair of Custodian Capital Ltd, a subsidiary of Mattioli Woods PLC, in January. Adds that Malcolm Naish has informed the board he intends to retire as chair and a non-executive director at the company's next annual general meeting. It is intended Gilbertson will success Naish on his retirement.

----------

Atalaya Mining PLC - Cyprus-based copper producer - Appoints Neil Gregson, who has over 30 years' experience of investing in mining and oil and gas companies, as a non-executive director. From 2010 to 2020 he was a Managing Director at JP Morgan Asset Management where, as a member of the equity team, he was a portfolio manager investing in mining and energy companies globally.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Mar 2024 14:30

UK shareholder meetings calendar - next 7 days

Wednesday 13 March 
abrdn China Investment Co LtdGM re liquidation
Safestore Holdings PLCAGM
Wincanton PLCGM re takeover by CEVA Logistics
Thursday 14 March 
Angus Energy PLCGM
Bank of Georgia Group PLCGM re acquisition of Ameriabank CJSC
Blackrock Sustainable American Income Trust PLCAGM
Friday 15 March 
BlackRock Energy & Resources Income Trust PLCAGM
Chrysalis Investments LtdAGM
Quantum Exponential Group PLCGM re delisting from AQSE
TruSpine Technologies PLCAGM (adjourned 2022)
United Oil & Gas PLCGM re fundraise and share sub-division
Monday 18 March 
MGC Pharmaceuticals LtdGM re change of company name to Argent Biopharma
Schroder European Real Estate Investment Trust PLCAGM
Tuesday 19 March 
BlackRock Throgmorton Trust PLCAGM
Crest Nicholson Holdings PLCAGM
Eco Animal Health Group PLCGM re share buybacks
Gresham House Renewable Energy VCT 1 PLCAGM
Gresham House Renewable Energy VCT 2 PLCAGM
Nuformix PLCAGM
Scirocco Energy PLCGM re requisitioned resolution to implement cash strategy
Various Eateries PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 Mar 2024 10:31

IN BRIEF: Nuformix announces subscription to raise GBP150,000

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
23 Oct 2023 12:38

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis.

Read more
18 Sep 2023 10:20

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year.

Read more
17 Aug 2023 15:43

UK shareholder meetings calendar - next 7 days

Friday 18 August 
Adams PLCAGM
ME Group International PLCGM re proposed share buyback
Oxford BioDynamics PLCGM re placing
Pathfinder Minerals PLCGM re disposal of the subsidiary
Monday 21 August 
Calculus VCT PLCAGM
Home REIT PLCGM re changes to the investment policy
Tuesday 22 August 
Cake Box Holdings PLCAGM
ReNeuron Group PLCAGM
RUA Life Sciences PLCAGM
Smoove PLCAGM
STM Group PLCAGM
Wednesday 23 August 
Brandshield Systems PLCAGM
James Latham PLCAGM
LifeSafe Holdings PLCGM re shareholder circular
Momentum Multi-Asset Value Trust PLCGM re appointment of the liquidators
Sovereign Metals LtdGM re share placement options
Thor Energy PLCGM re proposed share consolidation
Thursday 24 August 
Ananda Developments PLCAGM
Concurrent Technologies PLCAGM
CyanConnode Holdings PLCAGM
Nuformix PLCAGM
Oryx International Growth Fund LtdAGM
ThomasLloyd Energy Impact Trust PLCAGM
ThomasLloyd Energy Impact Trust PLCGM re market purchases of its own ordinary shares
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 May 2023 12:45

Nuformix loss narrows; near-term goal to focus on NXP002 asset

(Alliance News) - Nuformix PLC on Monday reported a narrowed annual loss as it made progress on optimising costs and furthering its lead asset, NXP002.

Read more
18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Apr 2023 12:14

Nuformix raises GBP70,000 to fund NXP002 programme

(Alliance News) - Nuformix PLC on Monday said it has raised GBP70,000 through a subscription for 35.0 million new shares at a price of 0.20 pence each.

Read more
27 Mar 2023 18:42

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Feb 2023 12:12

Nuformix progresses NXP002 trial after acquiring human tissue

(Alliance News) - Nuformix PLC on Wednesday said that, despite having to wait longer than expected, human disease tissue has now been acquired for its NXP002 programme.

Read more
13 Dec 2022 14:54

Nuformix interim loss virtually flat as continues work on drugs

(Alliance News) - Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs.

Read more
23 Sep 2022 21:02

TRADING UPDATES: Neometals swings to loss; Funding Circle strikes deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
18 Aug 2022 16:01

UK shareholder meetings calendar - next 7 days

Friday 19 August 
Braemar Shipping Services PLCAGM
Citius Resources PLCAGM
Next Fifteen Communications Group PLCGM re acquisition of M&C Saatchi
Volex PLCAGM
Monday 22 August 
African Pioneer PLCAGM
Argentex Group PLCAGM
Nostrum Oil & Gas PLCGM operational update
Ondo InsurTech PLCAGM
Sabien Technology Group PLCGM re broker option
Scottish Investment Trust PLCGM re recombination of assets with JPMorgan Global Growth & Income plc
Trackwise Designs PLCAGM
Tuesday 23 August 
Bezant Resources PLCAGM
Livermore Investments Group LtdAGM
Xtract Resources PLCAGM
Wednesday 24 August 
Amur Minerals CorpGM subsidiary sale
Creightons PLCAGM
Goldstone Resources LtdAGM
Thursday 25 August 
Ince Group PLCGM fundraising
McBride PLCGM increase in borrowing limit
NatWest Group PLCGM re approval of special dividend
Nuformix PLCAGM
Triple Point Energy Efficiency Infrastructure Co PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
10 Aug 2022 11:14

IN BRIEF: Nuformix shares rise on tolerability studies completion

Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.